International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France.
Eur J Cancer Prev. 2011 Jan;20(1):33-9. doi: 10.1097/cej.0b013e32833f0c8e.
The incidence of hepatocellular carcinoma (HCC) in Mongolia is far higher than that of any other cancer in the country, and among the highest worldwide. The relative importance of infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) is unclear. We reviewed (i) medical records for 963 patients with HCC and 941 patients with cirrhosis admitted for the first time to the National Cancer Center of Mongolia and the National Center for Communicable Diseases, respectively, from 2000 to 2009,and (ii) articles published from 1990 to 2010 on the seroprevalence of hepatitis B surface antigen (HBsAg) and antibodies against hepatitis C virus (anti-HCV) among individuals with and without liver disease. Among those with HCC, the seroprevalence of HBsAg, anti-HCV and dual infections was 50, 27 and 21%, respectively. Corresponding percentages among the patients with cirrhosis were 40, 39, and 20%. In both diseases, HCV infection was relatively more prevalent in women than in men and, in cirrhosis, inpatients older than 45 years of age. In healthy individuals,from published articles, anti-HCV seroprevalence steadily increased with age (from 3% at age 0-5 years to 34% at age ≥ 50 years), whereas HBsAg seroprevalence stayed constant at about 8%. The future benefit of childhood vaccination against HBV in Mongolia will be undermined by the consequences of a severe HCV epidemic and a uniquely high burden of dual infections.
蒙古的肝细胞癌 (HCC) 发病率远高于该国其他任何一种癌症,在全球范围内也属于高发地区。乙型肝炎病毒 (HBV) 和丙型肝炎病毒 (HCV) 感染的相对重要性尚不清楚。我们回顾了 2000 年至 2009 年期间,963 名 HCC 患者和 941 名首次因肝硬化入住蒙古国家癌症中心和国家传染病中心的患者的医疗记录,以及 1990 年至 2010 年期间发表的关于乙型肝炎表面抗原 (HBsAg) 和丙型肝炎病毒抗体 (抗-HCV) 在肝病患者和非肝病患者中的血清流行率的文章。在 HCC 患者中,HBsAg、抗-HCV 和双重感染的血清流行率分别为 50%、27%和 21%。肝硬化患者的相应百分比分别为 40%、39%和 20%。在这两种疾病中,HCV 感染在女性中比在男性中更为普遍,在肝硬化中,45 岁以上的住院患者中更为普遍。在健康人群中,根据已发表的文章,抗-HCV 的血清流行率随着年龄的增长而稳步上升(从 0-5 岁时的 3%上升到≥50 岁时的 34%),而 HBsAg 的血清流行率则保持在约 8%。蒙古儿童乙型肝炎疫苗接种的未来获益将受到 HCV 流行和双重感染负担独特高的影响而受到削弱。